患者

1502例既往或目前已知的胃肠道肿瘤患者，正在接受胃肠道肿瘤监测。

Patients: 1502 patients with known previous or current cancer of the gastrointestinal tract and undergoing surveillance for gastrointestinal cancer.

方法

WLI组(WLI组)或LCI组(LCI组)。

Intervention: WLI followed by LCI examination (WLI group) or LCI followed by WLI examination (LCI group).

测量

在第一次检查中诊断出1个或1个以上的咽、食管或胃肿瘤病变(主要结果)，在第一次检查中诊断出1个或1个以上的肿瘤病变(次要结果)。

Measurements: Diagnosis of 1 or more neoplastic lesions in the pharynx, esophagus, or stomach in the first examination (primary outcome) and 1 or more neoplastic lesions overlooked in the first examination (secondary outcome).

结果

WLI组752例，LCI组750例。 在首次检查中诊断出1个或1个以上肿瘤病变的患者中，LCI患者的比例高于WLI患者(750例患者中有60例，8.0% [95% CI, 6.2% - 10.2%] vs 752例患者中有36例，4.8% [CI, 3.4% - 6.6%]; 风险比，1.67 [CI, 1.12 - 2.50; P = 0.011)。 LCI组肿瘤的漏诊率低于WLI组(750例患者中有5例，0.67% [CI, 0.2%至1.6%] vs 752例患者中有26例，3.5% [CI, 2.3%至5.0%]; 风险比，0.19 [CI, 0.07 ~ 0.50])。

Results: 752 patients were assigned to the WLI group and 750 to the LCI group. The percentage of patients with 1 or more neoplastic lesions diagnosed in the first examination was higher with LCI than with WLI (60 of 750 patients or 8.0% [95% CI, 6.2% to 10.2%] vs. 36 of 752 patients or 4.8% [CI, 3.4% to 6.6%]; risk ratio, 1.67 [CI, 1.12 to 2.50; P = 0.011]). The proportion with overlooked neoplasms was lower in the LCI group than in the WLI group (5 of 750 patients or 0.67% [CI, 0.2% to 1.6%] vs. 26 of 752 patients or 3.5% [CI, 2.3% to 5.0%]; risk ratio, 0.19 [CI, 0.07 to 0.50]).